Courtesy of Twitter. Worth researching this company.29 Sep 2020 12:52
Stifel is a quality investment bank with strengths in biotech and pharma, and they pick their clients wisely and typically work with mid and larger caps and not small caps, so I surmise they have done their due diligence and see long term potential.
Pretty sure we’ve had this discussion with you before Simmo. Nothing wrong with being cautious but AIM can work on sentiment & pipeline as you well know. If this test comes to market (it very much sounds it will), the current market cap will be history. I do appreciate you reminding us again though, but maybe try a different approach next time.
Where’s Mapp? We could do with him busting out a rhyme about AIM being corrupt to calm the nerves a bit. I can’t be arsed to trade here. Looking forward to the massive value being realised in the near future.